Tibotec's Intelence is approved for use with other antiretrovirals to treat HIV
Tibotech Therapeutics' Intelence (etravirine) has been approved on an accelerated basis by the FDA for HIV combination therapy. The tablet is the first new non-nucleoside reverse transcriptase inhibitor (NNRTI) to be introduced in nearly 10 years and also the first NNRTI to show antiviral activity in patients with NNRTI-resistant virus. As such, it breaks new ground in the treatment of HIV patients, said Tibotec, a division of Ortho Biotech Products.
